Sangamo Therapeutics Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript
Good morning, everyone. My name is Gena Wang. I'm SMID cap biotech analyst at Barclays. Welcome to our fifth Gene Editing and Gene Therapy Summit. It is my great pleasure to introduce our next speaker, Sandy Macrae, President and Chief Executive Officer from Sangamo Therapeutics. Sandy, I hand over to you for introduction.
Good morning, Gena. It's always a pleasure to be here with you. And thank you to the team for putting together and running these slides for me. So can we go to the next slide, please. As always, we guide you to our forward-looking statements.
Next slide, please. And I want to describe a genomic medicine company. I want to describe Sangamo and its unique and novel science that we have driven forward and delivered on clinical stage programs. And underpinning that, we have our own manufacturing that allows us to be in control of our product and our fate.
Next slide, please. And
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
